On Wednesday, Shares of Targa Resources Corp (NYSE:TRGP), added 3.52% and closed at $48.59 in the last trading session. The last trading range of the stock ranges between $46.54 and $49.08. Targa Resources Corp. (TRGP) (“TRC”, the “Company” or “Targa”) recently stated third quarter 2016 results.
Third Quarter 2016 Financial Results
Third quarter 2016 net income (loss) attributable to Targa Resources Corp. was ($10.7) million contrast to $12.7 million for the third quarter of 2015.
The Company stated earnings before interest, income taxes, depreciation and amortization, and other non-cash items (“Adjusted EBITDA”) of $245.3 million for the third quarter of 2016 contrast to $311.3 million for the third quarter of 2015 (see the section of this release entitled “Targa Resources Corp. – Non-GAAP Financial Measures” for a negotiation of Adjusted EBITDA, distributable cash flow, gross margin and operating margin, and reconciliations of such measures to their most directly comparable financial measures calculated and presented in accordance with U.S. generally accepted accounting principles (“GAAP”)).
Insulet Corporation (NASDAQ:PODD), jumped 0.57% and closed at $35.58 in the last trading session. The last trading range of the stock ranges between $33.48 and $35.70. The company’s Market capitalization is $2.02 Billion with the total Outstanding Shares of 57.43 million. Insulet Corporation (PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Administration System, recently declared it will host an Shareholder Day on November 16, 2016, in Boston, Massachusetts. The presentation will begin at 10:30 a.m. (Eastern Time) followed by a question and answer session, and is expected to end at 2:00 p.m., with product exhibits to follow.
Presentations will be given by the following members of administration:
Patrick Sullivan, Chairman and Chief Executive Officer
Shacey Petrovic, President and Chief Operating Officer
Aiman Abdel-Malek, Senior Vice President, Advanced Technology and Engineering
Charles Alpuche, Senior Vice President, Global Manufacturing and Operations
Michael Levitz, Senior Vice President and Chief Financial Officer
Omeros Corporation (NASDAQ:OMER), gained 9.75% and closed at $10.13 in the last trading session. The last trading range of the stock ranges between $9.60 and $10.35. During the 52-week trading session the minimum price at which share price traded, registered at $7.20 and reached to max level of $16.80. Omeros Corporation (OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market in addition to orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system, recently declared recent highlights and developments in addition to financial results for the third quarter of 2016, which include:
3Q 2016 total and OMIDRIA® revenues were $11.3 million. Revenues from OMIDRIA sales rose 248% from the prior year quarter and 13% from 2Q 2016. OMIDRIA units sold by wholesalers to customers (“sell-through”) raised by 18% over the second quarter.
Net loss in 3Q 2016 was $14.0 million, or $0.34 per share, which included $3.1 million ($0.08 per share) of non-cash expenses. Net loss in the prior year quarter was $19.9 million or $0.53 per share, which included $2.7 million ($0.07 per share) of non-cash expenses.
Positive data from Phase 2 clinical trials of OMS721 in both kidney disorders and hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA).